--- title: "Genscript Chairman Joins Board of Nasdaq-Listed Associate Legend Biotech" description: "Genscript Biotech has announced that its chairman, Jiange (Robin) Meng, will join the board of its associate company, Legend Biotech Corporation, effective January 20, 2026. This appointment aims to s" type: "news" locale: "en" url: "https://longbridge.com/en/news/273529090.md" published_at: "2026-01-23T14:39:07.000Z" --- # Genscript Chairman Joins Board of Nasdaq-Listed Associate Legend Biotech > Genscript Biotech has announced that its chairman, Jiange (Robin) Meng, will join the board of its associate company, Legend Biotech Corporation, effective January 20, 2026. This appointment aims to strengthen ties between the two companies and enhance strategic coordination. Investors are advised to be cautious, as the latest analyst rating for Genscript's stock is a Sell, with a price target of HK$13.00. Genscript Biotech is a Hong Kong-listed life sciences company with a strategic interest in Legend Biotech, which is listed on Nasdaq. ### Claim 50% Off TipRanks Premium - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Genscript Biotech ( (HK:1548) ) has shared an update. Genscript Biotech has announced that its chairman and executive director, Jiange (Robin) Meng, has been appointed to the board of its associate company Legend Biotech Corporation, effective 20 January 2026, replacing outgoing director Li Zhu with a term running until Legend’s 2026 annual general meeting. The move strengthens board-level ties between Genscript and Legend, leveraging Meng’s extensive leadership, finance and corporate governance experience in the life sciences sector, and may enhance strategic coordination between the Hong Kong- and U.S.-listed companies, though investors are reminded to remain mindful of investment risks when trading Genscript’s shares. The most recent analyst rating on (HK:1548) stock is a Sell with a HK$13.00 price target. To see the full list of analyst forecasts on Genscript Biotech stock, see the HK:1548 Stock Forecast page. **More about Genscript Biotech** Genscript Biotech Corporation is a life sciences and biotechnology company listed in Hong Kong, providing products and services across the biotech value chain. The group has a strategic interest in Legend Biotech Corporation, a Nasdaq-listed associate focused on cell therapy and related biopharmaceutical innovations. **Average Trading Volume:** 9,674,275 **Technical Sentiment Signal:** Sell **Current Market Cap:** HK$29.95B ### Related Stocks - [01548.HK - GENSCRIPT BIO](https://longbridge.com/en/quote/01548.HK.md) - [LEGN.US - Legend Biotech](https://longbridge.com/en/quote/LEGN.US.md) - [BIB.US - Proshares Ultra Nasdaq Biotech](https://longbridge.com/en/quote/BIB.US.md) - [FBT.US - First Trust NYSE Arca Biotech Index Fd](https://longbridge.com/en/quote/FBT.US.md) - [BBH.US - VanEck Biotech ETF](https://longbridge.com/en/quote/BBH.US.md) - [ARKG.US - Ark Genomic Revolution ETF](https://longbridge.com/en/quote/ARKG.US.md) - [IBBQ.US - Invesco Nasdaq Biotechnology ETF](https://longbridge.com/en/quote/IBBQ.US.md) - [IBB.US - iShares Biotechnology ETF](https://longbridge.com/en/quote/IBB.US.md) - [XBI.US - SPDR S&P Biotech](https://longbridge.com/en/quote/XBI.US.md) - [PBE.US - Invesco Biotechnology & Genome ETF](https://longbridge.com/en/quote/PBE.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Kiora Pharmaceuticals 将在奥本海默第 36 届年度医疗生命科学会议上发表演讲 | Kiora Pharmaceuticals, Inc. 将于 2026 年 2 月 26 日下午 3:20（东部时间）在 Oppenheimer 第 36 届年度医疗生命科学会议上进行演讲。其投资者关系网站将提供现场直播网络广播，回放可在 | [Link](https://longbridge.com/en/news/276338683.md) | | Madrigal 制药因 Rezdiffra 的销售，第四季度收入大幅增长 | Madrigal 制药报告第四季度收入为 3.211 亿美元，较去年大幅增长，尽管出现了净亏损。该公司预计，由于疾病意识的提高，Rezdiffra 的销售将实现强劲增长，并计划与 FDA 就第二阶段试验设计进行咨询。MASH 管道已通过新项 | [Link](https://longbridge.com/en/news/276330392.md) | | 展望 Galapagos 的未来收益 | Galapagos（纳斯达克代码：GLPG）将于 2026 年 2 月 23 日公布季度财报，分析师预计每股收益（EPS）为 0.85 美元。投资者期待在之前每股收益错失 3.23 美元后能获得积极的指引，这导致股价上涨 4.38%。目前， | [Link](https://longbridge.com/en/news/276462319.md) | | 阿伯丁集团有限公司在 Tectonic Therapeutic, Inc. $TECX 中建立了价值 559 万美元的头寸 | 阿伯丁集团（Aberdeen Group plc）在 Tectonic Therapeutic, Inc.（纳斯达克代码：TECX）中获得了约 559 万美元的新头寸，在第三季度购买了 356,176 股。这项投资约占 Tectonic 股 | [Link](https://longbridge.com/en/news/276507461.md) | | NEOS 投资管理有限责任公司减少了其在 Crinetics Pharmaceuticals, Inc. $CRNX 的股票持仓 | NEOS Investment Management LLC 在第三季度将其在 Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) 的持股减少了 61.6%，目前持有 22,300 股，价值 929, | [Link](https://longbridge.com/en/news/276532688.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.